An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Trial Profile

An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Rocapuldencel-T (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ADAPT
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 02 Apr 2018 According to an Argos Therapeutics media release, the Company is currently finalizing an amendment to the protocol and plans to submit it to the FDA prior to the interim data analysis planned for the second quarter of 2018.
    • 11 Nov 2017 According to an Argos Therapeutics media release, the company anticipates next planned interim data analysis during the first half of 2018, subject to the agreement with the FDA on a revised protocol.
    • 11 Nov 2017 According to an Argos Therapeutics media release, update on the immunology data from this trial presented in the poster session at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top